ArticleBMC health services research2021
The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
Article in BMC health services research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Impact of national volume-based procurement on physicians' antimicrobial prescribing behaviours: an interrupted time series analysis of 1200 prescriptions in a tertiary hospital.Annals of medicine · 2026Article
- Drug price trends, regional disparities, and supply shortages under China's National Volume-Based Procurement: a nationwide analysis (2018-2024).BMC health services research · 2026Article
- Assessing regional disparities and trends in health resource allocation from sub-provincial cities in China.Annals of medicine · 2025Article
- The impacts of the national volume-based procurement policy on the chronic disease medication market in China's public hospitals: a case study of medications for diabetes.BMC health services research · 2025Article
- Changes in antibiotic use associated with the National Centralized Drug Procurement policy in China from 2019 to 2023.Scientific reports · 2025Article
- Intended and Unintended Impacts of '4+7' Volume-Based Drug Procurement on the Use of Drugs in China: A Natural Experimental Study.Healthcare (Basel, Switzerland) · 2025Article
- Testing the unintended cost effects of health policies for generic substitutions: the case of China's National Volume-Based Procurement (NVBP) policy.Health policy and planning · 2025Article
- Impacts of Chinese national centralized volume-based procurement policy targeting meropenem on prescription of designated antimicrobials for inpatients: an interrupted time series analysis.Frontiers in pharmacology · 2025Article
- Clinical pharmacist-led Antimicrobial Stewardship under volume-based procurement: a retrospective quasi-experimental study on rational use and resistance control.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Impact of China's National Volume-Based Procurement policy exclusively for insulin on the volume, expenditure and price: an interrupted time series analysis in Guangdong Province.Frontiers in public health · 2025Article
- Effects of national volume-based procurement policy on the usage and expenditure of platinum antineoplastic drugs in China: an interrupted time series study.Frontiers in pharmacology · 2025Article
- Article
- Increased consumption of cardiovascular drugs under volume-based procurement (VBP) policy: demand release or assessment inducing?Health research policy and systems · 2024Article
- The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China.BMC health services research · 2024Article
- Trends in antidiabetic drug use and expenditure in public hospitals in Northwest China, 2012-21: a case study of Gansu Province.BMC health services research · 2024Article
- The cost of total hip arthroplasty: compare the hospitalization costs of national centralized procurement and national volume-based procurement.Frontiers in public health · 2024Article
- Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.Frontiers in pharmacology · 2024Article
- The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.International journal for equity in health · 2023Article
- Article
- Improving access to medicines and beyond: the national volume-based procurement policy in China.BMJ global health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2019, Chinese government implemented volume-based procurement of 25 drugs in 4 municipalities and 7 sub-provincial cities, i.e. "4 + 7" policy. Competitive bidding was conducted by the government based on the annual agreed procurement volume submitted by each public medical institution in pilot cities. Pilot cities were required to implement bid winning results in March 2019 and the use volume of bid winning products was examined to ensure the completion of agreed procurement volume. In the policy, an oral antibiotic (cefuroxime) was included. Given the current condition of the irrational use of antibiotics in China, this study aims to evaluate the impact of "4 + 7" policy on the use of policy-related antibiotics.
methodsThis study used drug purchase data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. Oral antibiotic drugs related to "4 + 7" policy were selected as study samples, including cefuroxime and 12 antibiotic drugs that have an alternative relationship with cefuroxime in clinical use. Purchase volume and expenditures were selected as outcome variables, and were measured using Defined Daily Doses (DDDs) and Chinese yuan, respectively. Segmented linear regression analysis with interrupted time series was adopted to examine the effect of "4 + 7" policy.
resultsAfter the implementation of "4 + 7" policy, the overall volume of cefuroxime and its alternative drugs increased from 9.47 million DDDs to 13.42 million DDDs, with an increase of 41.8 %. The results of segmented linear regression showed that the volume of cefuroxime significantly increased 161.16 thousand DDDs after "4 + 7" policy (95 % CI: 59.43 to 262.90, p-value = 0.004). The volume of alternative drugs significantly increased 273.65 thousand DDDs (95 % CI: 90.17 to 457.12, p-value = 0.006). The overall "4 + 7" policy-related antibiotics significantly increased 436.31 thousand DDDs (95 % CI: 190.81 to 681.81, p-value = 0.001) after "4 + 7" policy.
conclusionsThis study provides evidence that the implementation of "4 + 7" volume-based procurement policy was associated with significant increases in the volume of policy-related antibiotic drugs. The increase in antibiotic use after the policy needs special attention and vigilance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.